MOUNTAIN VIEW, Calif., June 11 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Klaas Prins, Ph.D., senior scientist, Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries attending the Population Approach Group in Europe (PAGE) 16th Annual Meeting, to be held in Copenhagen, Denmark on June 13-15, 2007, in two separate presentations.
Dr. Prins will present during two conference sessions on applications in model-based drug development, each of which will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Dr. Prins' presentations are:
-- June 13: Integrated modeling and simulation of clinical response and drop-out of D2 receptor agonists in patients with early Parkinson's Disease. Dr. Prins will present this case study as part of a dedicated conference session on modeling disease and disease progression. The session will include applied examples of disease progression modeling in several therapeutic areas, and will describe research on how modeling and simulation has been used to understand and predict disease dynamics and to address key drug development questions. -- June 14: Modeling of plasma aldosterone concentrations after prokinetic 5-HT4 receptor agonists: forming an integrated simulation framework for summary statistic and subject-level data. Dr. Prins will present this case study as part of a poster session focused on the value of modeling and simulation for endocrine disorders. The session will include applications of model-based clinical pharmacology in diabetes, obesity and gastrointestinal motility disorders, and will describe research on how modeling and simulation has been used to assess drug attributes and support the design of future clinical trials.
Additional information can be found at http://www.page-meeting.org.
"Model-based drug development continues to show value for enhancing understanding of complicated diseases in quantitative terms, and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Application of drug-disease models using longitudinal data to simulate expected clinical response of new compounds can support critical program strategy. The use of predictive models to describe early biomarker behavior can serve as a quantitative framework to support programmatic decision-making, such as dose selection for new compounds to be tested in future clinical trials. Pharsight is pleased to continue its active participation at the PAGE Annual Meeting, and we look forward to sharing these case examples with industry colleagues and fellow practitioners of modeling and simulation."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight CorporationCONTACT: Investors, Jennifer Beugelmans, +1-646-201-5447, or DouglasSherk, +1-415-896-6820, or Media, Jennifer Saunders, +1-646-201-5431, allof the EVC Group for Pharsight Corporation
Web site: http://www.pharsight.com/
